Here are six orthopedic surgeons making headlines this week:
The Latest
Here are eight key notes on spine and orthopedic device companies:
The FDA approved Centinel Spine's prodisc L lumbar total disc replacement device for two-level indications on April 14.
Biotechnology company Vomaris plans to expedite the approval of its bioelectric V.Dox system after research has indicated that viruses are killed upon exposure to the technology, the Daily Independent reports.
More than 1.2 million spinal surgeries are performed in the U.S. each year, including spinal fusion, decompression and discectomy procedures, according to the National Center for Health Statistics. And the volume of elective lumbar fusions is rising across the U.S.,…
Melissa Erickson, MD, is a spine surgeon with Duke University Medical Center in Durham, N.C.
The widespread suspension of elective surgeries due to the COVID-19 pandemic is causing significant economic difficulties for device companies and practices in the orthopedic industry.
NuVasive is reducing executive and board member compensation and taking other temporary cost-cutting measures during the COVID-19 pandemic, which has significantly lowered elective procedure volumes.
Financial relief provided under the Coronavirus Aid, Relief and Economic Security Act won't be enough to keep musculoskeletal care providers afloat after the COVID-19 crisis, the American Association of Orthopaedic Surgeons said in an April 10 letter to congressional leaders.
Johnson & Johnson subsidiary Ethicon is scrapping plans to buy Takeda Pharmaceutical's TachoSil surgical patch for controlling bleeding, Reuters reports.